NGeneBio started as KT’s internal corporate venture in 2010.
KT’s ICT & Big Data technology combined with precision medicine platform technology to develop the nation’s first “massive genomics platform” which led to the foundation of NGeneBio as an independent company in October 2015.
The company launched NGS-based hereditary breast / ovarian cancer panel (BRCAaccuTest™) with clinical analysis S/W (NGeneAnalysis™) and received CE-IVD mark in Jun/2017.
We have been working on research and development with the cooperation of the anticancer diagnosis project team, domestic and foreign hospitals and biotech companies. We have been striving to secure the technology and develop business model of mid- to long-term perspectives through external patent license-in in addition to the company’s own patent discovery.
We are doing our utmost to achieve our goal of global healthcare service provider based on four core values of challenging execution, respect for life, human resource development and customer trust, and we look forward to your continued support and interest.